KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $5.0 billion.

  • Alnylam Pharmaceuticals' Liabilities and Shareholders Equity rose 1713.09% to $5.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.6 billion, marking a year-over-year increase of 1424.4%. This contributed to the annual value of $5.0 billion for FY2025, which is 1713.09% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Liabilities and Shareholders Equity is $5.0 billion, which was up 1713.09% from $4.9 billion recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $5.0 billion in Q4 2025 and a low of $3.3 billion during Q1 2021
  • In the last 5 years, Alnylam Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $3.7 billion in 2021 and averaged $3.9 billion.
  • In the last 5 years, Alnylam Pharmaceuticals' Liabilities and Shareholders Equity soared by 4279.85% in 2021 and then crashed by 510.09% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Liabilities and Shareholders Equity stood at $3.6 billion in 2021, then dropped by 2.66% to $3.5 billion in 2022, then grew by 7.99% to $3.8 billion in 2023, then rose by 10.71% to $4.2 billion in 2024, then increased by 17.13% to $5.0 billion in 2025.
  • Its last three reported values are $5.0 billion in Q4 2025, $4.9 billion for Q3 2025, and $4.6 billion during Q2 2025.